Category: Pharma

Meteoric Biopharmaceuticals, a first-generation biopharma enterprise and a renowned name in the global bio-pharmaceutical landscape with over 100 products. The company has chalked out aggressive growth plans and is working continuously towards introducing novel, cost-effective ingredients and formulations in the biopharmaceutical space through innovative research. The company also plans to launch more concept-based finished nutraceuticals products.   Meteoric Biopharmaceuticals currently has 10 patents and over 50 trademarks to its name.  It has two production area and two fully functional labs cum R&D center for a Microbiology and Enzyme Portfolio.   …

Read More

The New Reality of work for Health & Pharma Sector As part of its recognition lists announcement, Great Place To Work® India has recently announced India’s Best Workplaces™ in Pharmaceuticals, Healthcare and Biotech 2022 as their 1st edition of the recognition announcement. The global authority on workplace culture, Great Place To Work®, assesses various organizations as a part of their research, based on which the companies get identified as Best Workplaces, every year.   This year, 70 organizations in the Pharmaceuticals, Healthcare and Biotech sectors undertook the assessment, basis which the research indicates…

Read More

MUMBAI, India, May 20, 2022 /PRNewswire/ — Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Abiraterone Acetate Tablets USP, 500 mg, the generic version of Zytiga®1 Tablets, 500 mg, of Janssen Biotech Inc. According to IQVIA™ sales data for the 12-month period ending March 2022, the Zytiga® Tablets, 500 mg market2 achieved annual sales of approximately $260.2 million*. Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 49 ANDA’s pending approval with the U.S.…

Read More

MUMBAI, India, March 21, 2022 /PRNewswire/ — Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for its Lacosamide Tablets1 USP, 50 mg, 100 mg, 150 mg and 200 mg, the generic version of Vimpat®2 Tablets, 50 mg, 100 mg, 150 mg and 200 mg of UCB, Inc. The company plans to launch the product immediately. Commenting on the development, Robert Crockart, Chief Commercial Officer, Glenmark Pharmaceuticals Ltd, said, “The FDA approval for generic Lacosamide Tablets USP reiterates our ongoing…

Read More

– Data Integrity Early Warning System Assists Pharmaceutical Clients In Proactively Identifying and Managing Data Integrity Challenges in line with Regulatory Guidelines MUMBAI, India, March 8, 2022 /PRNewswire/ — Ankura Consulting, LLC (“Ankura”), a leading global expert services and advisory firm, today announced the expansion of its Pharmaceutical and Biopharma Regulatory Compliance offering with the addition of a Pharmaceutical Data Integrity solution within the Data and Technology practice, bolstering its comprehensive client advisory capabilities. With this solution, Ankura has enhanced its team of experts to support pharmaceutical clients’ compliance with the…

Read More